Briefs: Indoco Remedies and Panacea Biotec
Panacea Biotec receives LoA from CMSS
Panacea Biotec receives LoA from CMSS
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Former Global Head of IT & Digital Transformation at Biocon Biologics steps into enterprise-wide technology leadership role
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Subscribe To Our Newsletter & Stay Updated